NASDAQ: JSPR Jasper Therapeutics, Inc. 8-K

Jasper Therapeutics board member Christian Nolet resigns; Lucas appointed to Audit Committee

Filed May 21, 2026 · Period ending May 15, 2026 · ~1 min read

Key Changes

medium

Christian Nolet resigned from the Board of Directors and all Board committees effective May 15, 2026. The company stated his departure was not due to any disagreement on operations, policies, or practices.

Item 5.02 verify on EDGAR →
low

Dr. Svetlana Lucas was appointed to the Audit Committee to help maintain Board committee composition following Nolet's departure.

Item 5.02 verify on EDGAR →

Summary

Jasper Therapeutics disclosed a board transition on May 15, 2026, when director Christian Nolet resigned from the Board and all committees he served on.

The company emphasized that Nolet's resignation was not the result of any disagreement with management regarding the company's operations, policies, or practices—standard language meant to reassure investors that the departure was amicable and not a signal of internal conflict. To fill the gap on the Audit Committee, the Board appointed Dr. Svetlana Lucas, an existing director, to that committee.

For retail investors, board changes at small biotech companies like Jasper warrant attention primarily when they involve key leadership roles or suggest strategic disagreements. In this case, the departure appears routine and the company moved quickly to maintain committee structure. Investors should monitor whether additional board changes follow or if the company announces a replacement director in coming months.